NVMDF News and Press, Novamind Inc. From 03/16/22

TORONTO, ON / ACCESSWIRE / March 16, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce it has been selected by Mind Medicine, Inc. (NASDAQ:MNMD), (NEO:MM...

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. TORONTO, ON / ACCESSWIRE / March 11, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novami...

Novamind (OTCPK:NVMDF) is conducting a phase 2 trial to evaluate psilocybin, a psychedelic prodrug compound, for major depressive disorder. The company said it completed first patient randomization at its Draper, Utah research site. Last year, the company was awarded two licenses fr...

First patient randomization completed at Draper, Utah research site TORONTO, ON / ACCESSWIRE / March 9, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to conduct a pha...

Novamind Inc. (CNSX: NM)(OTCQB: NVMDF) reported its financial results for the fiscal second quarter ending December 31, 2021). All results were reported in Canadian dollars, unless otherwise specified. Novamind delivered total revenue of $2,452,540,  an increase of 32% ov...

Novamind press release (OTCPK:NVMDF): Q2 GAAP EPS of -C$0.08. Revenue of C$2.45M (+89.9% Y/Y). For further details see: Novamind GAAP EPS of -$0.08, revenue of $2.45M

Record high revenue of $2,452,540, +32% over the previous quarter Opened new outpatient clinic located in downtown Salt Lake City Strong pipeline of clinical trials for psychedelics and mental health treatments In January 2022, successfully closed the acquisition of an Arizon...

TORONTO, ON / ACCESSWIRE / February 22, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today launched Healing Stories, a series of case studies with first-hand accounts of patient expe...

Innovative treatment is a candidate to become regular service offering for healthcare workers TORONTO, ON / ACCESSWIRE / February 16, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicin...

Clinical trial underway at Novamind's Draper, UT research site TORONTO, ON / ACCESSWIRE / February 9, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce it is ...